Rhythm Pharmaceuticals received FDA approval to market its genetic obesity drug Imcivree for children as young as 2 years old.
Friday’s action will let the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.